SCHEMBL156114

SCHEMBL156114

O=S(=O)(O)c1ccccc1C=Cc1ccc(N=C=S)c(N=C=S)c1S(=O)(=O)O.[Na].[Na]

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD1 O60671 1/20 0.50
P2RY6 Q15077 1/20 0.50
SENP2 Q9HC62 5/20 0.39
SENP1 Q9P0U3 5/20 0.39
SENP3 Q9H4L4 4/20 0.39
SUMO2 P61956 3/20 0.39
SUMO1 P63165 3/20 0.39
SENP7 Q9BQF6 3/20 0.39
RAD51 Q06609 4/20 0.39
ALDH1A1 P00352 3/20 0.39
TDP1 Q9NUW8 3/20 0.39
KDM4E B2RXH2 2/20 0.39
USP2 O75604 2/20 0.39
LTA P01374 2/20 0.39
CYP3A4 P08684 2/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
P2RX3 P56373 2/20 0.39
HSD17B10 Q99714 2/20 0.39
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2834143 0.99 RAD1 (0.51) RAD1P2RY6SENP2SENP1SENP3
SCHEMBL29015815 0.85 SENP2 (0.40) RAD1P2RY6SENP2SENP1SENP3
SCHEMBL29978315 0.85 RAD1 (0.51) RAD1P2RY6SENP2SENP1SENP3
SCHEMBL5364759 0.85 RAD1 (0.51) RAD1P2RY6SENP2SENP1SENP3
SCHEMBL344713 0.85 RAD1 (0.51) RAD1P2RY6SENP2SENP1SENP3
SCHEMBL1976079 0.81 RAD1 (0.42) RAD1P2RY6SENP2SENP1SENP3
SCHEMBL6533768 0.80 RAD51 (0.44) RAD1P2RY6SENP2SENP1SENP3
SCHEMBL6533773 0.80 RAD51 (0.44) RAD1P2RY6SENP2SENP1SENP3
SCHEMBL10622332 0.80 APEX1 (0.47) RAD1P2RY6SENP2SENP1SENP3
SCHEMBL9358944 0.76 RAD1 (0.55) RAD1P2RY6SENP2SENP1SENP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230065890-A1 ADAPTORS FOR NUCLEIC ACID CONSTRUCTS IN TRANSMEMBRANE SEQUENCING OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2023-03-02 US disclosed
US-20220177937-A1 POLYNUCLEOTIDE SYNTHESIS METHOD, KIT AND SYSTEM OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2022-06-09 US disclosed
US-11352664-B2 Adaptors for nucleic acid constructs in transmembrane sequencing OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2022-06-07 US disclosed
US-20220090192-A1 METHOD OF NANOPORE SEQUENCING OF CONCATENATED NUCLEIC ACIDS OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2022-03-24 US disclosed
US-20190376132-A1 ADAPTORS FOR NUCLEIC ACID CONSTRUCTS IN TRANSMEMBRANE SEQUENCING OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2019-12-12 US disclosed
US-20180291440-A1 ADAPTORS FOR NUCLEIC ACID CONSTRUCTS IN TRANSMEMBRANE SEQUENCING OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2018-10-11 US disclosed
US-20170321266-A1 ADAPTORS FOR NUCLEIC ACID CONSTRUCTS IN TRANSMEMBRANE SEQUENCING OXFORD NANOPORE TECHNOLOGIES LTD. (GB) 2017-11-09 US disclosed
US-20120100530-A1 ENZYME MUTANT OXFORD NANOPORE TECHNOLOGIES LIMITED (GB) 2012-04-26 US disclosed
US-20120058468-A1 ADAPTORS FOR NUCLEIC ACID CONSTRUCTS IN TRANSMEMBRANE SEQUENCING OXFORD NANOPORE TECHNOLGIES LIMITED (GB) 2012-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11352664-B2 Adaptors for nucleic acid constructs in transmembrane sequencing MTREX, PHAX, TARBP1 RAD1 2402/4885P2RY6 1477/4885SENP2 3454/4885
US-20230065890-A1 ADAPTORS FOR NUCLEIC ACID CONSTRUCTS IN TRANSMEMBRANE SEQUENCING MTREX, PHAX, TARBP1 RAD1 2402/4885P2RY6 1477/4885SENP2 3454/4885
US-20120058468-A1 ADAPTORS FOR NUCLEIC ACID CONSTRUCTS IN TRANSMEMBRANE SEQUENCING MTREX, PHAX, TARBP1 RAD1 2402/4885P2RY6 1477/4885SENP2 3454/4885
US-20120100530-A1 ENZYME MUTANT UNG, RNGTT, FEN1 RAD1 1848/4885P2RY6 3827/4885SENP2 421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.